Retatrutide for NAFLD / MASLD

Verdict: Published with Warning

Across 1 PubMed study, the evidence for Retatrutide in NAFLD / MASLD grades Tier B — preliminary evidence. Effective, but with safety or population caveats.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.52

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

B · Published with Warning

Confidence

84%

Highly consistent evidence

Evidence level

Single small RCT

How strongly each layer supports this effect

lower = less supportive

L1 ExamineGlobal benchmark

0.50

L3 MechanismPlausibility

0.50

L2 PubMedPrimary literature

0.55

L5 Clinical bodiesAuthoritative stance

0.55

L11 AI re-checkIndependent read

0.65

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.515
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 無高階證據可裁決
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (1)L2 · primary research & systematic reviews

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

PMID: 38858523 2024 RCT (phase 2a, randomized, double-blind, placebo-controlled; substudy of the obesity phase 2 trial) n = 98

Finding: Marked dose-dependent liver-fat reduction. Mean relative liver-fat change at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) vs +0.3% placebo (all P<0.001 vs placebo). Normal liver fat (<5%) was achieved by 27%/52%/79%/86% on 1/4/8/12 mg vs 0% placebo at 24 weeks; NAFLD/MASLD resolution rose further by 48 weeks (~89% on 8 mg, ~93% on 12 mg).

🟢 High quality Effect size: Mean relative liver-fat reduction ~ -81% to -82% with 8 mg / 12 mg at 24 weeks (placebo +0.3%)

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Cautious

Retatrutide is not currently approved by the FDA and is considered an investigational medication, with Eli Lilly currently evaluating its safety and efficacy in clinical trials. source↗

L4b EU EFSA

Neutral

Retatrutide is not currently approved by the FDA and is considered an investigational medication. source↗

L4d TW TFDA / 衛福部

Cautious

Retatrutide is not currently approved by the FDA and is considered an investigational medication, with Eli Lilly currently evaluating its safety and efficacy in clinical trials. source↗

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬1 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-nafld-INT-retatrutide-001 繁體中文版 →